---
title: "Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients | ADTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283351157.md"
description: "Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients | ADTX Stock News"
datetime: "2026-04-20T04:15:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283351157.md)
  - [en](https://longbridge.com/en/news/283351157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283351157.md)
---

# Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients | ADTX Stock News

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients | ADTX Stock News

### Related Stocks

- [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md)

## Related News & Research

- [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md)
- [Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV](https://longbridge.com/en/news/286637657.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)
- [Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | AZN Stock News](https://longbridge.com/en/news/286621973.md)